Trial Profile
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 31 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2024.
- 06 Jan 2022 Planned primary completion date changed from 30 Nov 2021 to 1 Jun 2024.